Biotechnology company developing gene therapies for genetic diseases using its non-viral gene therapy platform.
Generation Bio Co. is a pioneering genetic medicines company dedicated to advancing therapies aimed at treating both rare and prevalent diseases. The company boasts a robust portfolio that encompasses programs targeting a spectrum of conditions affecting the liver and retina, which are among its primary areas of focus. Beyond these, Generation Bio Co. is actively developing treatments for disorders affecting skeletal muscle, the central nervous system, and oncology.
Founded in 2016 and headquartered in Cambridge, Massachusetts, Generation Bio Co. initially operated under the name Torus Therapeutics, Inc. before rebranding itself in November 2017. Since its inception, the company has demonstrated a commitment to leveraging cutting-edge genetic medicine technologies to address unmet medical needs across various disease areas.
In pursuit of its mission, Generation Bio Co. utilizes innovative platforms and methodologies to design and develop transformative therapies. These efforts are aimed at delivering potentially curative treatments that can significantly improve the lives of patients affected by genetic diseases and disorders. The company's strategic approach integrates rigorous research, development, and collaboration with industry partners to advance its therapeutic pipeline.
With a strong emphasis on scientific innovation and patient-centric solutions, Generation Bio Co. continues to expand its capabilities and advance promising therapies through rigorous clinical development and regulatory pathways. The company remains at the forefront of genetic medicine, driven by a vision to redefine the treatment landscape for rare and prevalent diseases globally.